Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate intravitreal ranibizumab after vitrectomy for proliferative diabetic retinopathy
ChiCTR2500107615Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Cumulative incidence of major ocular complications within 3 months after treatment and Change in best corrected visual acuity (BCVA) at 3 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ChiCTR2500107615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107615.